PMC8039836_01
Blue arrows indicate the different lesions within the respiratory airway. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
gr1.jpg
PMC8039836_01_gr1.jpg
fig1
A bronchoscopy was performed and biopsies from small localized lesions revealed HPV 16 and 66. (Fig. 1, Fig. 2).
Needle 19G for the subcutaneous injection of bevasizumab. Left the drug connected to the needle inlet, without the protective sheath. Right, the 19G needle (RED arrow) inside the protective sheath (BLUE arrow) as it is inserted in the bronchoscope. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
gr3.jpg
PMC8039836_01_gr3.jpg
fig3
Local treatment with argon plasma coagulation (APC) for larger lesions and local treatment with subcutaneous bevasizumab (7.5mg) injection followed (Fig. 3).
Left; the blue arrow indicates the needle which is inserted in the spraying catheter (yellow arrow). The needle is connected to the inlet of the catheter red arrow. Right; Blue arrow indicates the drug (interferon-alpha), the spraying catheter is inside the bronchoscope and the green tip represent the stylet which is inside the catheter in order to make the catheter for stable when inserted in the bronchoscope. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
gr4.jpg
PMC8039836_01_gr4.jpg
fig4
In the region of the lesions we sprayed interferon-alpha (2b-recombinant) with a spraying catheter probe (Fig. 4, Fig. 5, Fig. 6).
Left; compression system, Right; after experimentation we used the presented compression system as it is connected on the right in order to enhance the spraying capability of the catheter.
gr6.jpg
PMC8039836_01_gr6.jpg
fig6
In the region of the lesions we sprayed interferon-alpha (2b-recombinant) with a spraying catheter probe (Fig. 4, Fig. 5, Fig. 6).